Clover Health Investments, Corp. operates as a Medicare Advantage insurer in the United States. The company through its software platform provides preferred provider organization and health maintenance organization health plans for Medicare-eligible consumers. Clover Health Investments, Corp. was founded in 2014 and is headquartered in Franklin, Tennessee.
IPO Year:
Exchange: NASDAQ
Website: cloverhealth.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/17/2024 | $6.00 | Buy | Craig Hallum |
| 10/7/2024 | $4.00 | Neutral | UBS |
| 2/25/2022 | $3.00 → $2.50 | Market Perform | SVB Leerink |
| 2/2/2022 | $7.00 → $3.00 | Underperform → Market Perform | Cowen & Co. |
| 2/2/2022 | $6.00 | Buy | Canaccord Genuity |
| 1/19/2022 | $3.00 | Market Perform | SVB Leerink |
| 1/10/2022 | $9.00 → $3.50 | Neutral | Citigroup |
| 1/7/2022 | $9.00 → $3.50 | Neutral → Underperform | Credit Suisse |
| 11/15/2021 | $8.00 → $9.00 | Neutral | Credit Suisse |
| 9/10/2021 | $7.00 | Underperform | Cowen & Co. |
The recent insider purchase at Clover Health Investments Corp. by Director Garipalli Vivek on June 20, 2024, has caught the attention of investors. Director Garipalli Vivek bought $1,000,426 worth of shares, acquiring 877,567 units at $1.14 per share, as reported in SEC Form 4. This insider purchase stands out among recent insider transactions at Clover Health. Looking at the previous transactions, there have been instances of insiders covering exercise/tax liability by selling shares, resulting in a decrease in their direct ownership percentages. For example, Reynoso Jamie L., Priest Brady Patrick, Toy Andrew, Sharp Aric R, Soares Karen, Chief Technology Officer Wai Conrad, and CEO Reynoso
10-Q - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)
8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)
DEFA14A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)
DEF 14A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)
8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)
144 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
S-8 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)
144 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
10-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)
8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)
SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
SC 13G - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
SC 13D/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
SC 13D/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)
Craig Hallum initiated coverage of Clover Health with a rating of Buy and set a new price target of $6.00
UBS initiated coverage of Clover Health with a rating of Neutral and set a new price target of $4.00
SVB Leerink reiterated coverage of Clover Health Investments with a rating of Market Perform and set a new price target of $2.50 from $3.00 previously
Cowen & Co. upgraded Clover Health Investments from Underperform to Market Perform and set a new price target of $3.00 from $7.00 previously
Canaccord Genuity initiated coverage of Clover Health with a rating of Buy and set a new price target of $6.00
SVB Leerink initiated coverage of Clover Health Investments with a rating of Market Perform and set a new price target of $3.00
Citigroup resumed coverage of Clover Health with a rating of Neutral and set a new price target of $3.50 from $9.00 previously
Credit Suisse downgraded Clover Health from Neutral to Underperform and set a new price target of $3.50 from $9.00 previously
Credit Suisse reiterated coverage of Clover Health Investments with a rating of Neutral and set a new price target of $9.00 from $8.00 previously
Cowen & Co. initiated coverage of Clover Health Investments with a rating of Underperform and set a new price target of $7.00
First quarter 2025 Medicare Advantage membership of 103,418, up 30% year-over-yearFirst quarter 2025 Total revenues of $462 million, up 33% year-over-yearMedicare Advantage medical costs are in line with expectations, underscoring the strength of Clover's technology-first care management modelMeaningful improvement across first quarter 2025 profitability metrics: GAAP Net loss of $1 million, as compared to a GAAP Net loss of $19 million a year agoAdjusted EBITDA of $26 million, up 279% year-over-yearAdjusted Net income of $25 million, up 322% year-over-year Improved Full Year 2025 Guidance: Average Medicare Advantage membership of 103,000 - 107,000, representing 30% growth year-over-year
USA News Group News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 6, 2025 /PRNewswire/ -- Healthcare is quickly evolving into a digital-first operation, where top executives in the sector are doubling down on artificial intelligence, automation and analytics to reduce costs and improve billing accuracy. This is according to results of a survey from Everest Group (and supported by Omega Healthcare), which showed 85% of senior healthcare executives believe AI will improve efficiencies over the next five years. Now that multitasking AI Agents are being referred to as hospitals' newest "employees", AI-powered electronic noses are detecting scents for health and enviro
WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a wholly owned subsidiary of Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company") and a leading AI-powered physician-enablement platform, today released research demonstrating how Counterpart Assistant ("CA") use is associated with better management of congestive heart failure ("CHF"). The analysis, titled "Driving Clinical Excellence in Chronic Disease: Counterpart Assistant's Role in Heart Failure Care," details the significant positive association among CHF patients between better clinical care and lower hospitalizations, and having a relationship with a PC
USA News Group News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, April 29, 2025 /CNW/ -- Artificial intelligence is making deeper inroads into western healthcare, targeting the slow grind of authorizations and paperwork that bog down patient care. Despite Bill Gates' prophecy about AI replacing doctors, the real push today is about supercharging physicians, not sidelining them. Recent moves by players such as like Avant Technologies, Inc. (OTCQB:AVAI), Amesite Inc. (NASDAQ:AMST), Oracle Corporation (NYSE:ORCL), Clover Health Investments, Corp. (NASDAQ:CLOV), and Alphabet Inc. (NASDAQ:GOOG, GOOGL)) are signaling just how fast this transformation is taking hold.
USA News Group News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, April 29, 2025 /PRNewswire/ -- Artificial intelligence is making deeper inroads into western healthcare, targeting the slow grind of authorizations and paperwork that bog down patient care. Despite Bill Gates' prophecy about AI replacing doctors, the real push today is about supercharging physicians, not sidelining them. Recent moves by players such as like Avant Technologies, Inc. (OTCQB:AVAI), Amesite Inc. (NASDAQ:AMST), Oracle Corporation (NYSE:ORCL), Clover Health Investments, Corp. (NASDAQ:CLOV), and Alphabet Inc. (NASDAQ:GOOG, GOOGL)) are signaling just how fast this transformation is taking hold.
WILMINGTON, Del., April 22, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that after four years of distinguished service, Lee A. Shapiro, a member of Clover Health's Board of Directors, has notified the Company of his intention not to stand for reelection to the Board of Directors in light of new responsibilities related to his assumption of the Chairmanship of the American Heart Association in the coming weeks. Mr. Shapiro will fulfill the remainder of his term as a member of the Board of Directors, ending his service as of June 10, 2025, the date of the Company's 2025 Annual Shareholders' meeting. "I
WILMINGTON, Del., April 21, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced its participation in the following investor conferences: CFO, Peter Kuipers, will present at the 2025 Bank of America Healthcare Conference on Wednesday, May 14, 2025, at 6:00 p.m. Eastern Time. A live webcast and replay of the presentation will be accessible from Clover Health's investor relations website at https://investors.cloverhealth.com/.CFO, Peter Kuipers, will participate in the 22nd Annual Craig-Hallum Institutional Investor Conference on Wednesday, May 28, 2025. About Clover Health:Clover Health (NASDAQ:CLOV) is a phy
WILMINGTON, Del., April 08, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that it will report first quarter 2025 financial results after market close on Tuesday, May 6, 2025. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on May 6, 2025, to discuss Clover Health's first quarter 2025 business and financial results. First Quarter 2025 Conference Call and Webcast Details: What: Clover Health's First Quarter 2025 Earnings Conference CallWhen: Tuesday, May 6, 2025, at 5:00 p.m. Eastern TimeDial In: To access the call via telephone please dial 800-274-8461 (for U.S. callers) or
WILMINGTON, Del., April 07, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced the appointment of Dr. Shelly Gupta as Chief Medical Officer ("CMO"). Dr. Gupta will oversee Clover's innovative clinical operations, quality initiatives, pharmacy operations, and precision-based chronic disease management programs, directly focusing on patient choice, provider autonomy, and delivering transparent, value-driven healthcare. Dr. Gupta brings extensive healthcare experience to Clover as a trained family practice physician with over a decade of experience in Medicare Advantage leadership and a proven record of enhanc
WILMINGTON, Del., March 03, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a leading AI-powered physician enablement platform, today announced it has partnered with Google Cloud to integrate Vertex AI Search into its flagship technology, Counterpart Assistant. This innovation gives providers on Counterpart Assistant a generative AI (gen AI) search experience across the breadth of a patient's digital health record to provide contextualized insights, and to make it easier to deliver value-based care. Counterpart is a subsidiary of Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"). Physicians struggle to access and synthesize the vast amounts of data within
First quarter 2025 Medicare Advantage membership of 103,418, up 30% year-over-yearFirst quarter 2025 Total revenues of $462 million, up 33% year-over-yearMedicare Advantage medical costs are in line with expectations, underscoring the strength of Clover's technology-first care management modelMeaningful improvement across first quarter 2025 profitability metrics: GAAP Net loss of $1 million, as compared to a GAAP Net loss of $19 million a year agoAdjusted EBITDA of $26 million, up 279% year-over-yearAdjusted Net income of $25 million, up 322% year-over-year Improved Full Year 2025 Guidance: Average Medicare Advantage membership of 103,000 - 107,000, representing 30% growth year-over-year
WILMINGTON, Del., April 08, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that it will report first quarter 2025 financial results after market close on Tuesday, May 6, 2025. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on May 6, 2025, to discuss Clover Health's first quarter 2025 business and financial results. First Quarter 2025 Conference Call and Webcast Details: What: Clover Health's First Quarter 2025 Earnings Conference CallWhen: Tuesday, May 6, 2025, at 5:00 p.m. Eastern TimeDial In: To access the call via telephone please dial 800-274-8461 (for U.S. callers) or
Full year 2024 GAAP Net loss from continuing operations improves by $164 million year-over-year Full year 2024 Adjusted EBITDA of $70 million, representing an increase of $112 million year-over-year Company well positioned to invest in membership growth and Clover Assistant technology, while maintaining strong profitability Issues full year 2025 guidance: Average Medicare Advantage membership of 103,000 - 107,000, representing 30% growth year-over-year at the midpointInsurance revenue between $1.800 billion and $1.875 billion, representing 37% growth year-over-year at the midpointAdjusted EBITDA profitability between $45 million and $70 millionAdjusted Net income between
WILMINGTON, Del., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"), today announced that it will report fourth quarter and full year 2024 financial results after market close on Thursday, February 27, 2025. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on February 27, 2025, to discuss Clover Health's fourth quarter and full year 2024 business and financial results. Fourth Quarter and Full Year 2024 Conference Call and Webcast Details: What: Clover Health's Fourth Quarter and Full Year 2024 Earnings Conference CallWhen: Thursday, February 27, 2025, at 5:00 p.m. Eastern TimeDial In: To access the call via tele
Delivers 9% Total Revenue growth year-to-date compared to prior year period Company improves 2024 year-to-date GAAP Net Loss from Continuing Operations by $117.4 million year-over-year and year-to-date Adjusted EBITDA by $87.2 million year-over-year Increases Full-Year 2024 guidance midpoint to target updated range of Adjusted EBITDA profitability of $55 million - $65 million, strongly positioning the Company to invest in membership growth opportunity for 2025 FRANKLIN, Tenn., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today reported financial results for the third quarter 2024. Management will host a co
FRANKLIN, Tenn., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"), today announced that it will report third quarter 2024 financial results after market close on Wednesday, November 6, 2024. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on November 6, 2024, to discuss Clover Health's third quarter 2024 business and financial results. Third Quarter 2024 Conference Call and Webcast Details: What: Clover Health's Third Quarter 2024 Earnings Conference CallWhen: Wednesday, November 6, 2024, at 5:00 p.m. Eastern TimeDial In: To access the call via telephone please dial 800-579-2543 (for U.S. callers) or 785-424-1
Total Revenue growth for the Second Quarter of 2024 of 11% year-over-year GAAP Net Income from Continuing Operations during the Second Quarter of 2024 of $7.2 million versus Second Quarter 2023 GAAP loss of $28.9 million Adjusted EBITDA profitability for the Second Quarter of 2024 of $36.2 million versus Second Quarter 2023 Adjusted EBITDA of $9.9 million Increases Full-Year 2024 guidance to Insurance Revenue of $1.35 billion - $1.375 billion and Adjusted EBITDA profitability of $50 million - $65 million FRANKLIN, Tenn., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enab
FRANKLIN, Tenn., July 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced that it will report second quarter 2024 financial results after market close on Monday, August 5, 2024. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on August 5, 2024, to discuss Clover Health's business and financial results. Second Quarter 2024 Conference Call and Webcast Details: What: Clover Health's Second Quarter 2024 Earnings Conference CallWhen: Monday, August 5, 2024, at 5:00 p.m. Eastern TimeDial I
First Quarter 2024 Insurance Revenue growth of 8% year-over-year First Quarter 2024 GAAP Net Loss from Continuing Operations of $23.2 million versus First Quarter 2023 loss of $79.7 million First Quarter Adjusted EBITDA profitability of $6.8 million versus prior period loss of $37.5 million Improves 2024 guidance to Insurance Revenue of $1.30 billion - $1.35 billion and Adjusted EBITDA profitability of $10 million - $30 million Maintains strong liquidity position and view that Company has sufficient capital for operating and growth needs. Board of Directors authorizes share repurchase program of up to $20 million of the Company's Class A Common Stock over the next two years FRANKLIN, Te
FRANKLIN, Tenn., April 23, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that it will report first quarter 2024 financial results after market close on Tuesday, May 7, 2024. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on May 7, 2024, to discuss the Company's business and financial results. First Quarter 2024 Conference Call and Webcast Details: What: Clover Health First Quarter 2024 Earnings Conference CallWhen: Tuesday, May 7, 2024, at 5:00 p.m. Eastern TimeDial In: To access the call via telephone please dial 800-579-2543 (for U.S. callers) or 785-424-1789 (for calle
WILMINGTON, Del., April 07, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced the appointment of Dr. Shelly Gupta as Chief Medical Officer ("CMO"). Dr. Gupta will oversee Clover's innovative clinical operations, quality initiatives, pharmacy operations, and precision-based chronic disease management programs, directly focusing on patient choice, provider autonomy, and delivering transparent, value-driven healthcare. Dr. Gupta brings extensive healthcare experience to Clover as a trained family practice physician with over a decade of experience in Medicare Advantage leadership and a proven record of enhanc
FRANKLIN, Tenn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a leading AI-powered physician enablement platform, today announced the appointment of David Tsay M.D., Ph.D as Chief Medical Officer (CMO). Dr. Tsay will play a key role in advancing Counterpart's clinical strategy and product roadmap for Counterpart Assistant, the company's proprietary AI-powered physician enablement software platform that empowers providers to deliver high-quality, cost-effective care. Counterpart is a subsidiary of Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"). David Tsay is a distinguished physician executive with deep expertise and over two decades of ex
FRANKLIN, Tenn., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health" or "Clover"), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced the appointment of Joseph Brand as Chief Operating Officer (COO) for its Medicare Advantage (MA) plan. Mr. Brand will oversee core MA operations and drive performance improvements, with a focus on improving healthcare delivery in New Jersey by leveraging operational efficiencies and technological innovation. Mr. Brand brings nearly 20 years of healthcare leadership experience, having held prominent positions in healthcare operation
FRANKLIN, Tenn., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced it has appointed Thomas L. Tran to the Company's Board of Directors (the "Board"), and as a member of the Audit Committee. "Tom Tran's appointment to our Board marks a significant enhancement to our strategic financial planning and execution capabilities. With his impressive track record at the helm of finance at public managed care organizations, Tom is uniquely qualified to help guide Clover Health as we advance o
FRANKLIN, Tenn., April 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement technology company, today announced the appointment of Peter Kuipers as Chief Financial Officer ("CFO"), effective as of the day after the filing of the Company's Quarterly Report on Form 10-Q for the quarter-ended March 31, 2024. With a wealth of experience and a proven track record in financial management, Mr. Kuipers will drive strategic financial initiatives around profitability, growth and potential new revenue streams. Recognized with the 2018 San Francisco Bay Area Public Company CFO of the Year Award for small to me
FRANKLIN, Tenn., March 07, 2024 (GLOBE NEWSWIRE) -- Today Clover Health ("Clover" or "the Company") announced Clay Thornton as the newly appointed Chief Financial Officer of its Medicare Advantage (MA) division. Thornton, with an impressive track record spanning over a decade of healthcare financial management and operational leadership, joins as the Company enters the next phase of its lifecycle, targeting Adjusted EBITDA profitability for the full-year 20241, while emphasizing a differentiated PPO-first product strategy supported by its state-of-the-art technology and care management platform. Thornton's expertise in driving financial strategies that bolster quality outcomes, member and
FRANKLIN, Tenn., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Clover Health (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, today announced the appointment of Karen Soares as General Counsel, effective October 31, 2023. Karen will serve on Clover's management team and will report to Andrew Toy, Chief Executive Officer of Clover. "Karen has been a tremendous asset to Clover over the years, providing strategic legal counsel and partnership as our business has continued to evolve. I'm delighted to have her serve as our General Counsel, as Clover will benefit from her healthcare exper
FRANKLIN, Tenn., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement company committed to improving health equity for seniors, today announced the appointment of Anna Loengard, M.D. to the Company's Board of Directors. Dr. Loengard is a highly accomplished physician executive with significant experience in both geriatric medicine and value based care models. She most recently served as Chief Medical Officer of AccentCare, an enterprise providing home health, hospice, and private care services across 31 states. Previously, Dr. Loengard served as Chief Medical Officer for Caravan Health, Chief
FRANKLIN, Tenn., July 26, 2022 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement company committed to improving health equity for seniors, today announced the appointment of Carladenise Armbrister Edwards, Ph.D., to the Company's Board of Directors. Dr. Edwards is an accomplished healthcare executive with nearly three decades of healthcare, nonprofit and government experience. Currently the Henry Ford Health System's Executive Vice President and Chief Strategy Officer, she leads the system's strategic planning efforts and partnership ventures, business development and transformation initiatives, governme
FRANKLIN, Tenn., May 09, 2022 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover" or "Clover Health"), a physician enablement company committed to improving health equity for seniors, today announced the appointment of Aric Sharp as Chief Executive Officer ("CEO") of Value Based Care for Clover. Sharp will spearhead all value based care operations for the company including for Clover Health Partners, Clover's Direct Contracting Entity ("DCE"). Sharp is recognized as a national leader on the healthcare transition to value, innovation, and physician practice management and is Chair-Elect of the American Medical Group Association. In his former role as Senior Vice Pr